The widespread effectiveness of mRNA-based vaccines has attracted considerable attention to the prospect of mRNA technology serving as a platform that can be used to develop an array of preventative and therapeutic medicines, including vaccines for infectious diseases and cancer treatments. While the extent to which mRNA platforms can be used to develop other drugs remains to be seen, what are the prospects and interest in terms of applicability? How is the current IP landscape around this technology? How are biopharma companies building their mRNA capabilities and in which key areas? Is licensing the favoured way to unlock the full potential of mRNA technologies?
Moderator: Klaas P. Zuideveld, CEO, Versameb 
